# Utah Medical Products Inc: financial statements, quarterly

UTMD · Nasdaq · CIK 706698 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/utmd.md) · [Financials](/companies/utmd/financials.md) · [Filings](/companies/utmd/filings.md) · [Insiders](/companies/utmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/utmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [12.5](/filings/0001096906-26-000395.md) | [12.3](/filings/0001096906-26-000395.md) | [11.3](/filings/0001096906-26-000395.md) | [10.4](/filings/0001096906-26-000395.md) | [10.0](/filings/0001096906-26-000395.md) | [9.2](/filings/0001096906-26-000395.md) | [9.7](/filings/0001096906-26-000767.md) | [10.0](/filings/0001096906-26-001210.md) | [9.8](/filings/0001096906-26-000395.md) | [9.0](/filings/0001096906-26-000395.md) | [8.7](/filings/0001096906-26-000767.md) | [8.5](/filings/0001096906-26-001210.md) |
| Cost of revenue | $m | [5.1](/filings/0001811884-24-000022.md) | [5.2 d](/filings/0001096906-26-000395.md) | [4.6](/filings/0001096906-25-000816.md) | [4.1](/filings/0001096906-25-001281.md) | [4.2](/filings/0001096906-25-001839.md) | [3.8 d](/filings/0001096906-26-000395.md) | [4.2](/filings/0001096906-26-000767.md) | [4.4](/filings/0001096906-26-001210.md) | [4.2](/filings/0001096906-25-001839.md) | [3.8 d](/filings/0001096906-26-000395.md) | [3.4](/filings/0001096906-26-000767.md) | [3.8](/filings/0001096906-26-001210.md) |
| Gross profit | $m | [7.4](/filings/0001096906-26-000395.md) | [7.1](/filings/0001096906-26-000395.md) | [6.8](/filings/0001096906-26-000395.md) | [6.3](/filings/0001096906-26-000395.md) | [5.8](/filings/0001096906-26-000395.md) | [5.3](/filings/0001096906-26-000395.md) | [5.5](/filings/0001096906-26-000767.md) | [5.6](/filings/0001096906-26-001210.md) | [5.6](/filings/0001096906-26-000395.md) | [5.3](/filings/0001096906-26-000395.md) | [5.3](/filings/0001096906-26-000767.md) | [4.8](/filings/0001096906-26-001210.md) |
| Research and development | $m | [0.1](/filings/0001811884-24-000022.md) | [0.1 d](/filings/0001096906-26-000395.md) | [0.3](/filings/0001096906-25-000816.md) | [0.3](/filings/0001096906-25-001281.md) | [0.2](/filings/0001096906-25-001839.md) | [0.1 d](/filings/0001096906-26-000395.md) | [0.2](/filings/0001096906-26-000767.md) | [0.1](/filings/0001096906-26-001210.md) | [0.2](/filings/0001096906-25-001839.md) | [0.2 d](/filings/0001096906-26-000395.md) | [0.2](/filings/0001096906-26-000767.md) | [0.2](/filings/0001096906-26-001210.md) |
| Selling, general and administrative | $m | [3.3](/filings/0001811884-24-000022.md) | not reported | [2.6](/filings/0001096906-25-000816.md) | [2.6](/filings/0001096906-25-001281.md) | [2.3](/filings/0001096906-25-001839.md) | not reported | [2.2](/filings/0001096906-26-000767.md) | [2.3](/filings/0001096906-26-001210.md) | [2.8](/filings/0001096906-25-001839.md) | not reported | [2.6](/filings/0001096906-26-000767.md) | [2.0](/filings/0001096906-26-001210.md) |
| Operating income | $m | [4.0](/filings/0001811884-24-000022.md) | [3.9 d](/filings/0001096906-26-000395.md) | [3.9](/filings/0001096906-25-000816.md) | [3.4](/filings/0001096906-25-001281.md) | [3.3](/filings/0001096906-25-001839.md) | [2.9 d](/filings/0001096906-26-000395.md) | [3.2](/filings/0001096906-26-000767.md) | [3.2](/filings/0001096906-26-001210.md) | [2.6](/filings/0001096906-25-001839.md) | [2.4 d](/filings/0001096906-26-000395.md) | [2.6](/filings/0001096906-26-000767.md) | [2.6](/filings/0001096906-26-001210.md) |
| Income tax | $m | [0.8](/filings/0001811884-24-000022.md) | [0.7 d](/filings/0001096906-26-000395.md) | [0.8](/filings/0001096906-25-000816.md) | [0.8](/filings/0001096906-25-001281.md) | [0.6](/filings/0001096906-25-001839.md) | [0.7 d](/filings/0001096906-26-000395.md) | [0.8](/filings/0001096906-26-000767.md) | [0.8](/filings/0001096906-26-001210.md) | [0.7](/filings/0001096906-25-001839.md) | [0.5 d](/filings/0001096906-26-000395.md) | [0.6](/filings/0001096906-26-000767.md) | [0.6](/filings/0001096906-26-001210.md) |
| Net income | $m | [3.9](/filings/0001096906-26-000395.md) | [4.3](/filings/0001096906-26-000395.md) | [4.0](/filings/0001096906-26-000395.md) | [3.5](/filings/0001096906-26-000395.md) | [3.6](/filings/0001096906-26-000395.md) | [2.9](/filings/0001096906-26-000395.md) | [3.0](/filings/0001096906-26-001210.md) | [3.0](/filings/0001096906-26-001210.md) | [2.6](/filings/0001096906-26-000395.md) | [2.6](/filings/0001096906-26-000395.md) | [2.6](/filings/0001096906-26-001210.md) | [2.7](/filings/0001096906-26-001210.md) |
| Diluted EPS | $ per share | [1.08](/filings/0001096906-26-000395.md) | [1.18](/filings/0001096906-26-000395.md) | [1.09](/filings/0001096906-26-000395.md) | [0.98](/filings/0001096906-26-000395.md) | [1.03](/filings/0001096906-26-000395.md) | [0.86](/filings/0001096906-26-000395.md) | [0.92](/filings/0001096906-26-000767.md) | [0.94](/filings/0001096906-26-001210.md) | [0.82](/filings/0001096906-26-000395.md) | [0.80](/filings/0001096906-26-000395.md) | [0.82](/filings/0001096906-26-000767.md) | [0.84](/filings/0001096906-26-001210.md) |
| Basic EPS | $ per share | [1.08](/filings/0001811884-24-000022.md) | not reported | [1.09](/filings/0001096906-25-000816.md) | [0.98](/filings/0001096906-25-001281.md) | [1.02](/filings/0001096906-25-001839.md) | not reported | [0.92](/filings/0001096906-26-000767.md) | [0.94](/filings/0001096906-26-001210.md) | [0.82](/filings/0001096906-25-001839.md) | not reported | [0.82](/filings/0001096906-26-000767.md) | [0.84](/filings/0001096906-26-001210.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [88.2](/filings/0001811884-23-000021.md) | [92.9](/filings/0001096906-25-000308.md) | [93.8](/filings/0001811884-24-000015.md) | [89.2](/filings/0001811884-24-000018.md) | [88.5](/filings/0001811884-24-000022.md) | [83.0](/filings/0001096906-26-000395.md) | [83.3](/filings/0001096906-25-000816.md) | [82.2](/filings/0001096906-25-001281.md) | [84.3](/filings/0001096906-25-001839.md) | [85.8](/filings/0001096906-26-001210.md) | [87.4](/filings/0001096906-26-000767.md) | [87.5](/filings/0001096906-26-001210.md) |
| Current assets | $m | [102](/filings/0001811884-23-000021.md) | [106](/filings/0001096906-25-000308.md) | [107](/filings/0001811884-24-000015.md) | [102](/filings/0001811884-24-000018.md) | [102](/filings/0001811884-24-000022.md) | [96.3](/filings/0001096906-26-000395.md) | [96.4](/filings/0001096906-25-000816.md) | [94.4](/filings/0001096906-25-001281.md) | [96.5](/filings/0001096906-25-001839.md) | [97.7](/filings/0001096906-26-001210.md) | [100](/filings/0001096906-26-000767.md) | [101](/filings/0001096906-26-001210.md) |
| Total assets | $m | [131](/filings/0001811884-23-000021.md) | [135](/filings/0001096906-25-000308.md) | [135](/filings/0001811884-24-000015.md) | [130](/filings/0001811884-24-000018.md) | [130](/filings/0001811884-24-000022.md) | [123](/filings/0001096906-26-000395.md) | [123](/filings/0001096906-25-000816.md) | [121](/filings/0001096906-25-001281.md) | [122](/filings/0001096906-25-001839.md) | [123](/filings/0001096906-26-001210.md) | [124](/filings/0001096906-26-000767.md) | [125](/filings/0001096906-26-001210.md) |
| Current liabilities | $m | [4.2](/filings/0001811884-23-000021.md) | [4.7](/filings/0001096906-25-000308.md) | [5.5](/filings/0001811884-24-000015.md) | [3.9](/filings/0001811884-24-000018.md) | [3.4](/filings/0001811884-24-000022.md) | [3.8](/filings/0001096906-26-000395.md) | [4.3](/filings/0001096906-25-000816.md) | [2.3](/filings/0001096906-25-001281.md) | [3.0](/filings/0001096906-25-001839.md) | [2.6](/filings/0001096906-26-001210.md) | [3.5](/filings/0001096906-26-000767.md) | [2.1](/filings/0001096906-26-001210.md) |
| Total liabilities | $m | [7.5](/filings/0001811884-23-000021.md) | [7.1](/filings/0001096906-25-000308.md) | [7.7](/filings/0001811884-24-000015.md) | [6.0](/filings/0001811884-24-000018.md) | [5.5](/filings/0001811884-24-000022.md) | [5.1](/filings/0001096906-26-000395.md) | [5.5](/filings/0001096906-25-000816.md) | [3.3](/filings/0001096906-25-001281.md) | [3.7](/filings/0001096906-25-001839.md) | [3.3](/filings/0001096906-26-001210.md) | [4.0](/filings/0001096906-26-000767.md) | [2.5](/filings/0001096906-26-001210.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0001096906-25-000308.md) | not reported | not reported | not reported | [0.0](/filings/0001096906-26-000395.md) | not reported | not reported | not reported | [0.0](/filings/0001096906-26-000395.md) | not reported | not reported |
| Shareholders' equity | $m | [124](/filings/0001811884-23-000021.md) | [128](/filings/0001096906-25-000308.md) | [128](/filings/0001811884-24-000015.md) | [124](/filings/0001811884-24-000018.md) | [124](/filings/0001811884-24-000022.md) | [117](/filings/0001096906-26-000395.md) | [117](/filings/0001096906-25-000816.md) | [118](/filings/0001096906-25-001281.md) | [118](/filings/0001096906-25-001839.md) | [119](/filings/0001096906-26-001210.md) | [120](/filings/0001096906-26-000767.md) | [122](/filings/0001096906-26-001210.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [5,121 d](/filings/0001811884-24-000022.md) | [5,332 d](/filings/0001096906-26-000395.md) | [5,276](/filings/0001096906-25-000816.md) | [2,762 d](/filings/0001096906-25-001281.md) | [3,856 d](/filings/0001096906-25-001839.md) | [2,937 d](/filings/0001096906-26-000395.md) | [4,464](/filings/0001096906-26-000767.md) | [2,873 d](/filings/0001096906-26-001210.md) | [3,878 d](/filings/0001096906-25-001839.md) | [3,477 d](/filings/0001096906-26-000395.md) | [3,109](/filings/0001096906-26-000767.md) | [1,383 d](/filings/0001096906-26-001210.md) |
| Capital expenditure | $k | [186 d](/filings/0001811884-24-000022.md) | [90.0 d](/filings/0001096906-26-000395.md) | [22.0](/filings/0001096906-25-000816.md) | [110 d](/filings/0001096906-25-001281.md) | [89.0 d](/filings/0001096906-25-001839.md) | [9.0 d](/filings/0001096906-26-000395.md) | [184](/filings/0001096906-26-000767.md) | [51.0 d](/filings/0001096906-26-001210.md) | [27.0 d](/filings/0001096906-25-001839.md) | [109 d](/filings/0001096906-26-000395.md) | [130](/filings/0001096906-26-000767.md) | [134 d](/filings/0001096906-26-001210.md) |
| Dividends paid | $k | [1,071 d](/filings/0001811884-24-000022.md) | [1,071 d](/filings/0001096906-26-000395.md) | [1,089](/filings/0001096906-25-000816.md) | [1,081 d](/filings/0001096906-25-001281.md) | [1,052 d](/filings/0001096906-25-001839.md) | [1,038 d](/filings/0001096906-26-000395.md) | [1,017](/filings/0001096906-26-000767.md) | [1,001 d](/filings/0001096906-26-001210.md) | [988 d](/filings/0001096906-25-001839.md) | [977 d](/filings/0001096906-26-000395.md) | [989](/filings/0001096906-26-000767.md) | [987 d](/filings/0001096906-26-001210.md) |
| Share repurchases | $k | [0.0 d](/filings/0001811884-24-000022.md) | [0.0 d](/filings/0001096906-26-000395.md) | [2,990](/filings/0001096906-25-000816.md) | [6,403 d](/filings/0001096906-25-001281.md) | [3,866 d](/filings/0001096906-25-001839.md) | [6,709 d](/filings/0001096906-26-000395.md) | [3,221](/filings/0001096906-26-000767.md) | [3,487 d](/filings/0001096906-26-001210.md) | [653 d](/filings/0001096906-25-001839.md) | [994 d](/filings/0001096906-26-000395.md) | [128](/filings/0001096906-26-000767.md) | [78.0 d](/filings/0001096906-26-001210.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [3,634](/filings/0001811884-23-000021.md) | [3,636](/filings/0001811884-24-000015.md) | [3,639](/filings/0001811884-24-000018.md) | [3,639](/filings/0001811884-24-000022.md) | [3,618](/filings/0001096906-25-000816.md) | [3,532](/filings/0001096906-25-001281.md) | [3,478](/filings/0001096906-25-001839.md) | [3,310](/filings/0001096906-26-000767.md) | [3,246](/filings/0001096906-26-001210.md) | [3,207](/filings/0001096906-25-001839.md) | [3,185](/filings/0001096906-26-000767.md) | [3,184](/filings/0001096906-26-001210.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,183,818 at 2026-08-11, from the cover of the [10-Q filed 2026-08-12](/filings/0001096906-26-001210.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.